Xeris Pharmaceuticals and the American Diabetes Association (ADA) announced a multi-year strategic partnership to enhance hypoglycemia education and awareness. The collaboration aims to emphasize the importance of prescribing glucagon, particularly ready-to-use formulations, for individuals with diabetes on blood glucose-lowering medications or those at high risk of severe hypoglycemia. This initiative aligns with the ADA's updated Standards of Care in Diabetes—2025.
The partnership will involve developing educational materials and training resources for healthcare professionals and patients living with diabetes. A national awareness campaign will also be launched to inform the public about who is at risk for severe hypoglycemia and the necessity of having ready-to-use glucagon as a safety net. This effort seeks to address the low rates of appropriate glucagon prescriptions, despite severe hypoglycemia being responsible for over 202,000 emergency department visits annually.
John Shannon, Xeris' CEO, stated that severe hypoglycemia is associated with up to a three-time increased risk of death in people with diabetes. The collaboration underscores a mutual commitment to ensure patients can confidently manage severe low blood glucose emergencies by having ready-to-use glucagon readily available.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.